Sunitinib

2 Drugs classified under this active ingredient

Tyrosine Kinase Inhibitor. Sunitinib 12.5 mg, 25 mg, 50 mg.
Hard Caps. 28 X 12.5/25/50 mg
GIST and MRCC, recommended dose is 50 mg taken orally once/d, for 4 consecutive weeks, followed by a 2-week rest period (Schedule 4/2) to comprise a complete cycle of 6 weeks.
pNET, recommended dose is 37.5 mg taken orally once/d without a scheduled rest period.
Advanced Renal Cell Carcinoma, GI Stromal Tumor: after dis. progress. on or intoler. to imatinib mesylate.
Pancreatic Neuroendocrine Tumors (pNET): Tmt. of unresectable or metast., well different. pancreatic neuroendocrine tumours (pNET) with dis. progress.
C/I: Hypersens.

Protein Kinase Inhibitor. Sunitinib 12.5, 25, 50 mg.
CAPS: 28×12.5, 25, 50 mg. GIST, MRCC- 50 mg ×1/d, for 4 consec. wks., follow. by a 2-week rest period (Schedule 4/2) to comprise a complete cycle of 6 wks. pNET- 37.5 mg ×1/d without a scheduled rest period. Dose adjust., Safety, tolerability GIST, MRCC, dose modific. in 12.5 mg steps may be applied based on individ. safety & tolerab. dly. dose should not exceed 75 mg nor be decr. below 25 mg. pNET, dose modific. in 12.5 mg steps may be appl. individ. See lit.
Tmt. of GI stromal tumor after dis. progress. on or intoleran. to imatinib mesylate. Tmt. of advance. renal cell carcin. Tmt. of unresect. or metast. , well different. pancreatic neuroendocr. tumour. with dis. progress.
C/I: Hypersens.